GleamWall
中文EN

SKYE Skye Bioscience, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1516551 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.5%
TTM EPS YoY126.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-220.3%
ROA-162.4%
ROIC (approx.)-557.6%
Asset turnover—

Leverage & solvency

Liabilities / assets73.2%
Debt / equity0.00x
Current ratio1.36x
Interest coverage-4,388.42x

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.32M$3.94M$7.94M$11.47M$9.36M$14.34M$7.20M$7.79M
SG&A expense$3.66M$3.87M$4.74M$3.43M$3.91M$3.91M$4.56M$4.55M
Operating income$26,317-$11.06M-$12.67M-$14.90M-$13.26M-$18.24M-$11.76M-$10.67M
Interest expense$3,299$3,299$2,199$0$0$0$1,452-$46,914
Pretax income$69,126-$10.78M-$12.51M-$14.44M-$12.75M-$17.62M-$11.10M-$9.75M
Income tax$0$3,400$0$0$0$3,400$2,000$0
Net income$69,126-$10.79M-$12.51M-$14.44M-$12.75M-$17.62M-$11.10M-$9.75M
EBITDA$57,642-$10.90M-$12.50M-$14.72M-$13.09M-$18.06M-$11.58M-$10.49M
EPS (basic)0.01-0.27-0.32—-2.57-0.44-0.28—
EPS (diluted)0.01-0.27-0.32—-2.57-0.44-0.28—
Weighted avg. shares (diluted)4.99M39.69M39.68M—4.96M39.66M39.65M—
Balance sheet
Cash & equivalents$4.82M$8.07M$8.15M$5.88M$18.44M$23.84M$46.42M$68.42M
Short-term investments$0$2.00M$8.96M$19.85M$16.87M$24.75M$12.80M$0
Current assets$5.04M$10.96M$18.57M$27.09M$39.92M$50.58M$63.03M$70.83M
PP&E, net$20,430$32,939$756,077$898,930$1.03M$1.17M$1.30M$1.43M
Total assets$5.07M$11.03M$19.42M$28.31M$41.32M$52.16M$64.79M$72.76M
Current liabilities$3.71M$11.53M$10.40M$8.21M$8.37M$8.31M$5.32M$4.34M
Total liabilities$3.71M$11.53M$10.40M$8.29M$8.49M$8.48M$5.54M$4.61M
Shareholders' equity$1.36M-$497,307$9.01M$20.02M$32.84M$43.68M$59.25M$68.15M
Shares outstanding4.42M35.14M35.13M4.17M30.99M30.99M30.97M30.97M
Cash flow statement
Operating cash flow-$5.13M-$7.12M-$8.56M-$9.77M-$13.36M-$10.75M-$9.19M-$8.17M
Capital expenditure$0$0$0$0$0$0$6,312$50,024
Free cash flow-$5.13M-$7.12M-$8.56M-$9.77M-$13.36M-$10.75M-$9.19M-$8.22M
Investing cash flow$2.00M$7.14M$10.90M-$2.80M$7.97M-$11.86M-$12.81M$90,410
Financing cash flow-$116,712-$101,014-$71,525$11,413$0$18,158$0$5,618
Depreciation & amortization$31,325$157,598$172,886$180,009$178,898$187,066$177,379$175,293
Stock-based compensation$1.80M$1.27M$1.50M$1.62M$1.91M$2.03M$2.20M$2.09M

Free plan shows the latest 8 periods; Pro shows all 63 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.